Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 PK, efficacy and safety comparison of CT-P10 vs Rituxan vs MabThera in rheumatoid arthritis
2013-004555-21Phase 3Completed
- Sponsor
- Celltrion
- Start
- Jan 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab in rheumatoid arthritis (RA) (3 arms), sponsored by Celltrion. Primary endpoint: Co-primary pharmacokinetic endpoints (Part 1, first 24 weeks). Started Jan 2014; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2013-004555-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004555-21.